Arvind Ravi

1.6k total citations
24 papers, 716 citations indexed

About

Arvind Ravi is a scholar working on Surgery, Molecular Biology and Oncology. According to data from OpenAlex, Arvind Ravi has authored 24 papers receiving a total of 716 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Surgery, 9 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Arvind Ravi's work include Bladder and Urothelial Cancer Treatments (10 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Immune cells in cancer (4 papers). Arvind Ravi is often cited by papers focused on Bladder and Urothelial Cancer Treatments (10 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Immune cells in cancer (4 papers). Arvind Ravi collaborates with scholars based in United States, Russia and Netherlands. Arvind Ravi's co-authors include Donald E. Ingber, Benjamin Matthews, Kaustabh Ghosh, Akiko Mammoto, Charles K. Thodeti, Phillip A. Sharp, Gad Getz, Allan M. Gurtan, Arjun Bhutkar and Christopher B. Burge and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Arvind Ravi

22 papers receiving 699 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arvind Ravi United States 10 303 134 130 120 115 24 716
Hui Dong China 15 586 1.9× 108 0.8× 213 1.6× 71 0.6× 29 0.3× 51 860
Monika Deshpande United States 17 370 1.2× 55 0.4× 190 1.5× 40 0.3× 41 0.4× 23 752
Ling Luo China 17 413 1.4× 170 1.3× 60 0.5× 48 0.4× 27 0.2× 43 993
Jacob Kach United States 15 660 2.2× 134 1.0× 157 1.2× 52 0.4× 174 1.5× 20 1.1k
Ikuo Matsuda Japan 16 196 0.6× 165 1.2× 55 0.4× 94 0.8× 38 0.3× 58 735
Meng Zhu China 20 941 3.1× 156 1.2× 188 1.4× 41 0.3× 156 1.4× 57 1.4k
Jinghan Wang China 17 569 1.9× 149 1.1× 289 2.2× 149 1.2× 36 0.3× 41 881
Hongmei Shen China 16 433 1.4× 236 1.8× 83 0.6× 22 0.2× 70 0.6× 37 1.0k
Paul Kogut United States 16 511 1.7× 58 0.4× 137 1.1× 23 0.2× 137 1.2× 21 918
Laurence Delacroix Belgium 17 709 2.3× 159 1.2× 133 1.0× 148 1.2× 48 0.4× 27 1.0k

Countries citing papers authored by Arvind Ravi

Since Specialization
Citations

This map shows the geographic impact of Arvind Ravi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arvind Ravi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arvind Ravi more than expected).

Fields of papers citing papers by Arvind Ravi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arvind Ravi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arvind Ravi. The network helps show where Arvind Ravi may publish in the future.

Co-authorship network of co-authors of Arvind Ravi

This figure shows the co-authorship network connecting the top 25 collaborators of Arvind Ravi. A scholar is included among the top collaborators of Arvind Ravi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arvind Ravi. Arvind Ravi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jurić, Ivan, Emily E. Fink, Arvind Ravi, et al.. (2025). Single-cell RNA-sequencing of BCG naïve and recurrent non-muscle invasive bladder cancer reveals a CD6/ALCAM-mediated immune-suppressive pathway. npj Precision Oncology. 9(1). 318–318.
2.
Abdelnaser, Anwar, Arvind Ravi, Bicky Thapa, et al.. (2025). Impact of histological subtypes in patients receiving first-line treatment with enfortumab vedotin/pembrolizumab in advanced metastatic urothelial cancer.. Journal of Clinical Oncology. 43(16_suppl). 4575–4575.
3.
Ravi, Praful, Dory Freeman, Jonathan Thomas, et al.. (2024). Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer. Journal for ImmunoTherapy of Cancer. 12(2). e008215–e008215. 2 indexed citations
4.
Berg, Stephanie, Charlene Mantia, Matthew Mossanen, et al.. (2024). Correlation of circulating tumor DNA (ctDNA) dynamics with clinical response in patients with muscle-invasive bladder cancer (MIBC) undergoing trimodality therapy (TMT).. Journal of Clinical Oncology. 42(16_suppl). e16606–e16606. 1 indexed citations
5.
6.
Matsuda, Satoru, Ajinkya Revandkar, Taronish D. Dubash, et al.. (2023). TGF-β in the microenvironment induces a physiologically occurring immune-suppressive senescent state. Cell Reports. 42(3). 112129–112129. 37 indexed citations
7.
8.
McGregor, Bradley A., Lucia Kwak, Charlene Mantia, et al.. (2022). Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial.. Journal of Clinical Oncology. 40(6_suppl). TPS588–TPS588. 6 indexed citations
9.
Zarif, Talal El, Elio Adib, Clary B. Clish, et al.. (2022). Comprehensive metabolomic profiling of plasma from patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors (ICI) or platinum-based chemotherapy (PBC).. Journal of Clinical Oncology. 40(6_suppl). 565–565. 1 indexed citations
10.
Graubert, Aaron, François Aguet, Arvind Ravi, Kristin Ardlie, & Gad Getz. (2021). RNA-SeQC 2: efficient RNA-seq quality control and quantification for large cohorts. Bioinformatics. 37(18). 3048–3050. 47 indexed citations
11.
Alessandrino, Francesco, Rahul Gujrathi, Amin H. Nassar, et al.. (2019). Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors. European Urology Oncology. 3(5). 680–686. 13 indexed citations
12.
Parnes, Aric & Arvind Ravi. (2016). Polycythemia and Thrombocytosis. Primary Care Clinics in Office Practice. 43(4). 589–605. 2 indexed citations
13.
Gurtan, Allan M., Arvind Ravi, Peter B. Rahl, et al.. (2013). Let-7 represses Nr6a1 and a mid-gestation developmental program in adult fibroblasts. Genes & Development. 27(8). 941–954. 38 indexed citations
14.
Ravi, Arvind, Vikram R. Rao, & Joshua P. Klein. (2012). Dystextia. JAMA Neurology. 70(3). 404–404. 13 indexed citations
15.
Ravi, Arvind, Allan M. Gurtan, Madhu Kumar, et al.. (2012). Proliferation and Tumorigenesis of a Murine Sarcoma Cell Line in the Absence of DICER1. Cancer Cell. 21(6). 848–855. 51 indexed citations
16.
Zheng, Grace X. Y., et al.. (2011). Genome-wide impact of a recently expanded microRNA cluster in mouse. Proceedings of the National Academy of Sciences. 108(38). 15804–15809. 43 indexed citations
17.
Thodeti, Charles K., Benjamin Matthews, Arvind Ravi, et al.. (2009). TRPV4 Channels Mediate Cyclic Strain–Induced Endothelial Cell Reorientation Through Integrin-to-Integrin Signaling. Circulation Research. 104(9). 1123–1130. 303 indexed citations
18.
Ramasubramanian, Ashok, et al.. (2006). Computational Model for Early Cardiac Looping. Annals of Biomedical Engineering. 5 indexed citations
19.
Ramasubramanian, Ashok, et al.. (2006). Computational Model for Early Cardiac Looping. Annals of Biomedical Engineering. 34(8). 1355–1369. 48 indexed citations
20.
Ravi, Arvind, et al.. (2004). Molecular identification of bacteria associated with the coral reef ecosystem of Gulf of Mannar Marine Biosphere Reserve using 16S rRNA sequences. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hui Dong Breakdown of academic impact, for papers by Monika Deshpande Breakdown of academic impact, for papers by Ling Luo Breakdown of academic impact, for papers by Jacob Kach Breakdown of academic impact, for papers by Ikuo Matsuda Breakdown of academic impact, for papers by Meng Zhu Breakdown of academic impact, for papers by Jinghan Wang Breakdown of academic impact, for papers by Hongmei Shen Breakdown of academic impact, for papers by Paul Kogut Breakdown of academic impact, for papers by Laurence Delacroix
Rankless by CCL
2026